Nav1.2 Sodium Channel (SCN2A)
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Nav1.2 Sodium Channel (SCN2A)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NAV1-2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Nav1.2 Sodium Channel (SCN2A)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=NAV1-2" target="_blank">Search UniProt</a></td>
</tr>
</table>
Nav1.2 is a voltage-gated sodium-channel alpha subunit encoded by [SCN2A](/proteins/scn2a-protein). In the developing and mature forebrain, Nav1.2 is a major determinant of spike initiation and propagation in excitatory [neurons](/entities/neurons), especially in the axon initial segment and unmyelinated axon compartments.[@sanders2018][@wolff2017] SCN2A-associated disease is now recognized as a spectrum rather than a single syndrome, spanning early developmental epileptic encephalopathy, later-onset epilepsy, autism-spectrum phenotypes, intellectual disability, and mixed neurodevelopmental presentations.[@sanders2018][@wolff2017][@wolff2019]
...
Nav1.2 Sodium Channel (SCN2A)
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Nav1.2 Sodium Channel (SCN2A)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NAV1-2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Nav1.2 Sodium Channel (SCN2A)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=NAV1-2" target="_blank">Search UniProt</a></td>
</tr>
</table>
Nav1.2 is a voltage-gated sodium-channel alpha subunit encoded by [SCN2A](/proteins/scn2a-protein). In the developing and mature forebrain, Nav1.2 is a major determinant of spike initiation and propagation in excitatory [neurons](/entities/neurons), especially in the axon initial segment and unmyelinated axon compartments.[@sanders2018][@wolff2017] SCN2A-associated disease is now recognized as a spectrum rather than a single syndrome, spanning early developmental epileptic encephalopathy, later-onset epilepsy, autism-spectrum phenotypes, intellectual disability, and mixed neurodevelopmental presentations.[@sanders2018][@wolff2017][@wolff2019]
For NeuroWiki mechanistic mapping, Nav1.2 sits at the intersection of membrane excitability, network synchronization, synaptic integration, and activity-dependent circuit development. Because these axes also modulate vulnerability in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and related disorders, Nav1.2 is increasingly discussed as a translational node linking channelopathy biology to broader neurodegenerative network dysfunction.[@hedrich2019][@meisler2021]
Molecular Architecture And Biophysics
Like other Nav alpha subunits, Nav1.2 contains four homologous domains (DI-DIV), each with six transmembrane segments (S1-S6). The S4 segments carry positively charged residues that detect depolarization, and the pore/selectivity filter region enables fast inward sodium current during the action-potential upstroke.[@shen2019][@barbieri2023]
Functionally relevant features for Nav1.2 include:
- State-dependent gating transitions (closed, open, inactivated) that shape high-frequency firing.
- Developmental and cell-type-dependent expression differences that alter excitability setpoints.
- Sensitivity to background membrane potential, making Nav1.2 behavior tightly coupled to synaptic drive and interneuron tone.[@wolff2017][@wolff2019][@hedrich2019]
Small shifts in activation/inactivation kinetics can produce large network effects. This helps explain why SCN2A variants with different biophysical consequences can map to divergent phenotypes (for example, severe infantile epilepsy vs. later neurodevelopmental syndromes with less overt seizure burden).[@wolff2017][@wolff2019]
Physiologic Role In Neural Circuits
Nav1.2 contributes to:
- Action-potential initiation and forward propagation in cortical excitatory neurons.
- Spike timing precision required for cortical and hippocampal information transfer.
- Activity-dependent developmental circuit refinement.[@sanders2018][@wolff2017][@meisler2021]
From a systems perspective, Nav1.2 function affects excitation-inhibition balance. Excess or deficient sodium conductance can each destabilize circuits, but through different routes: hyperexcitability can increase pathologic synchronization, while reduced excitability can impair signal fidelity and adaptive plasticity.[@wolff2017][@hedrich2019][@meisler2021]
Disease Relevance
Current clinical-genetic literature emphasizes high phenotypic heterogeneity with mechanistically distinct subgroups that may need different treatment logic.[@wolff2017][@wolff2019] Major patterns include:
- Early-onset epileptic encephalopathy, often linked to variants that increase channel activity.
- Autism/intellectual-disability dominant presentations, often linked to reduced channel function.
- Intermediate mixed phenotypes that evolve across development.[@sanders2018][@wolff2017][@wolff2019]
Relevance to neurodegeneration-facing phenotypes
Nav1.2 is not a primary monogenic cause of classic late-life neurodegenerative disease, but channel-driven network vulnerability is mechanistically relevant to cognitive decline, seizure comorbidity, and circuit destabilization seen in [Alzheimer's disease](/diseases/alzheimers-disease) and other proteinopathy contexts.[@hedrich2019][@meisler2021] This is why sodium-channel biology remains part of biomarker and intervention discussions in neurodegeneration programs.
Therapeutic Targeting
Therapeutic strategy for SCN2A disorders is becoming mechanism-first rather than syndrome-first.[@sanders2018][@wolff2017][@wolff2019]
- In gain-of-function contexts, sodium-channel blockers may reduce hyperexcitability.
- In loss-of-function contexts, broad sodium-channel suppression can worsen symptoms and may be inappropriate.
- Precision treatment increasingly depends on variant-level functional interpretation and developmental stage.[@wolff2017][@wolff2019]
This precision-medicine framing is a useful template for NeuroWiki pathway reasoning: treatment effect depends on whether the intervention is pushing an already unstable circuit toward or away from its functional setpoint.
Research Frontiers
High-value frontiers include:
- Better genotype-biophysics-phenotype maps for variant classes.[@wolff2017][@wolff2019]
- Cell-type-specific model systems to define when and where Nav1.2 deficits matter most.[@scott2025]
- Trial designs that combine electrophysiologic readouts with cognitive/behavioral outcomes.[@sanders2018][@meisler2021]
See Also
- [SCN2A — Sodium Voltage-Gated Channel Alpha Subunit 2](/proteins/scn2a-protein)
- [Voltage-gated Sodium Channel Dysfunctions in Neurological Disorders](/mechanisms/voltage-gated-sodium-channel-dysfunctions-neurological-disorders)
- [Neuronal Hyperexcitability](/mechanisms/neuronal-hyperexcitability)
Brain Atlas Resources
The following resources from the Allen Brain Atlas provide expression and connectivity data for this protein/gene:
- [Allen Human Brain Atlas - Gene Expression](https://human.brain-map.org/microarray/search/show?search_term=SCN2A): Searchable gene expression database from adult human brain
- [Allen Brain Atlas - RNA Sequencing](https://human.brain-map.org/rnasearch): RNA sequencing data across brain regions
- [Allen Cell Type Atlas](https://celltypes.brain-map.org/): Single-cell transcriptomic data for cell type classification
- [Allen Mouse Brain Atlas](https://mouse.brain-map.org/): Comprehensive mouse brain gene expression database
- [BrainSpan Atlas of the Developing Human Brain](https://www.brainspan.org/): Developmental expression data across brain regions and ages
External Links
- [UniProt (SCN2A/Nav1.2)](https://www.uniprot.org/uniprot/Q99250)
- [NCBI Gene: SCN2A](https://www.ncbi.nlm.nih.gov/gene/6326)
References
[Sanders SJ et al, Progress in Understanding and Treating SCN2A-Mediated Disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29691040/)
[Wolff M et al, Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders (2017)](https://pubmed.ncbi.nlm.nih.gov/28379373/)
[Wolff M et al, Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond (2019)](https://pubmed.ncbi.nlm.nih.gov/31904126/)
[Hedrich UBS et al, SCN2A channelopathies: Mechanisms and models (2019)](https://pubmed.ncbi.nlm.nih.gov/31904120/)
[Meisler MH et al, Sodium channelopathies in neurodevelopmental disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33531663/)
[Shen H et al, Structures of human Na(v)1.7 channel in complex with auxiliary subunits and animal toxins (2019)](https://pubmed.ncbi.nlm.nih.gov/30765606/)
[Barbieri R et al, Voltage-Gated Sodium Channel Dysfunctions in Neurological Disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37240836/)
[Scott KEJ et al, Deciphering SCN2A: A comprehensive review of rodent models of Scn2a dysfunction (2025)](https://pubmed.ncbi.nlm.nih.gov/40884529/)